Harmony Biosciences Holdings (HRMY) Total Non-Current Liabilities (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Total Non-Current Liabilities data on file, last reported at $144.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 9.85% year-over-year to $144.1 million; the trailing twelve-month figure through Mar 2026 stood at $144.1 million (down 9.85% YoY), and the FY2025 full-year result was $149.3 million, down 9.51% from the prior year.
• Total Non-Current Liabilities fell to $144.1 million in Q1 2026, from $149.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $193.0 million in Q1 2022 to a low of $144.1 million in Q1 2026.
• A 5-year average of $173.3 million and a median of $177.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities grew 0.4% in 2022 and dropped 11.97% in 2025, its largest moves.
• Tracing HRMY's Total Non-Current Liabilities over 5 years: stood at $192.1 million in 2022, then declined by 5.97% to $180.7 million in 2023, then decreased by 8.7% to $165.0 million in 2024, then dropped by 9.51% to $149.3 million in 2025, then fell by 3.45% to $144.1 million in 2026.
• Business Quant data shows HRMY's Total Non-Current Liabilities at $144.1 million in Q1 2026, $149.3 million in Q4 2025, and $149.7 million in Q3 2025.